October 2026

the cjc-1295 story this month keeps circling back to one compound

This month, as [the FDA's zero-to-thirteen advisory committee vote against CJC-1295](https://fda.gov/media/184043/download) finished circulating through wellness clinic newsletters and biohacking forums, the conversation moved toward what comes next for GH stacks. CJC-1295 was the GHRH-receptor component in the most widely prescribed compounded GH protocol. Its fate had been settling since December 2024, when the Pharmacy Compounding Advisory Committee recorded the 0–13 vote, and its absence from clinic menus is now reshaping how practitioners explain their offerings. The compound it was most commonly paired with — GHRP-2, also known as pralmorelin — is in a genuinely different regulatory position. Not better. Not worse. Different: it has never been brought to a committee panel at all. Of all the GH-stack peptides that have dominated the compounding wellness market — CJC-1295, ipamorelin, GHRP-6, hexarelin — GHRP-2 is the only one that has yet to face a formal advisory committee review in the United States. That gap is the story.

The stack

why cjc-1295 and ghrp-2 were always sold as a pair

CJC-1295 and GHRP-2 were combined for a specific mechanistic reason. CJC-1295 works on the growth hormone-releasing hormone receptor, extending the natural GH pulse from the pituitary. GHRP-2 works through a different receptor — the ghrelin receptor, also called GHS-R1a — which amplifies the pulse independently. The two receptor pathways were understood to create a synergistic GH spike that neither compound alone produces. That is a receptor pharmacology argument, not a clinical outcome argument. No controlled human trial has tested the CJC-1295 and GHRP-2 combination against placebo for a fitness or recovery outcome in healthy adults. The GH spike is real — documented across multiple short-term human studies — but what the spike translates to in body composition, strength, or recovery in people who already have functioning pituitary glands is a separate question with sparse answers. The stack became culturally embedded before the outcome data existed.

The regulatory gap

ghrp-2 was nominated for review — the panel just never convened

The FDA works through nominations when evaluating GH-stack peptides. Compounding pharmacy associations and outsourcing facility groups nominate substances for the 503A and 503B bulk drug substances lists, which are the regulatory pathways for legally compounded peptides. GHRP-2 was nominated for the 503B list — for growth hormone deficiency and wasting syndrome — and the FDA commissioned [a scoping review](https://archive.hshsl.umaryland.edu/server/api/core/bitstreams/4ebb4113-854b-4231-94c5-f202e84b5206/content) to evaluate the evidence base. The scoping review exists. A committee panel decision does not, as of October 2026. The substance remains in the FDA's Category 2, which restricts routine compounding. The April 2026 wave that removed twelve peptides from restricted status did not include GHRP-2. So while the stacks it appeared in are being dismantled through committee votes — CJC-1295 at zero to thirteen, ipamorelin rejected separately — GHRP-2's own regulatory fate is pending a panel that has not been scheduled.

The one approval it has

in japan it is legally a diagnostic — the use is not what people think

There is exactly one jurisdiction where GHRP-2 carries formal regulatory approval. Kaken Pharmaceutical markets it in Japan as Pralmorelin, approved as a diagnostic agent for growth hormone deficiency. The mechanism that made it diagnostically useful: pralmorelin reliably and markedly increases plasma GH in healthy subjects, while the response in GHD patients is significantly blunted. A [peer-reviewed study formalizing the diagnostic cutoff](https://pubmed.ncbi.nlm.nih.gov/15230633/) used a peak GH threshold of 15.0 µg/L to separate GHD patients from healthy controls, and the Kaken diagnostic product remains on the Japanese market. The irony of GHRP-2's clinical profile is precise: it holds the most rigorous official recognition of any compound in the GH-stack category. The approved use is a single-dose injection to evaluate whether a patient's pituitary responds appropriately to a GH secretagogue stimulus. It is not a therapeutic approval, and it has nothing to do with muscle or recovery. The compound that anchored one half of the most popular GH stack in U.S. compounding medicine is officially, legally, a test to check whether your pituitary works.

What the human data covers

the evidence base is solid on one finding and sparse on everything else

The human studies on GHRP-2 are consistent on one point and thin on almost everything else. Acute administration produces measurable GH elevations across a range of doses, the effect is reproducible, and the response is reliable enough to underpin a clinical diagnostic. The short-term data also documents appetite stimulation — ghrelin receptor agonism is a known hunger signal, and it is not trivial in practice. What the evidence base does not include: long-term safety data on repeated subcutaneous injections in healthy adults without GH deficiency, and controlled trials showing that the GH elevation from GHRP-2 produces downstream changes in body composition or athletic performance in non-GHD populations. The [NCATS Inxight Drugs entry for pralmorelin](https://drugs.ncats.io/drug/E6S6E1F19M) reflects its profile as a research compound and diagnostic agent — not a therapeutic one. The fitness and recovery claims that made it popular in compounding wellness markets are extrapolations from the GH-release mechanism, not from outcome trials in healthy people.

Human-supported — PeptideFactCheck stance

the biology is documented, the verdict on compounding is pending, and the stack is already gone

GHRP-2 holds PeptideFactCheck's Human-supported evidence tier. The GH-releasing effect in humans is documented, reproducible, and sufficient to anchor a clinical diagnostic product in Japan. Human-supported does not mean the body composition and performance claims that drove its compounding market are supported — those extrapolate from mechanism to outcome without controlled human data. GHRP-2's regulatory position is unusual: its stack partner CJC-1295 was voted down zero to thirteen; ipamorelin and GHRP-6 have each faced their own committee reviews; GHRP-2 has not. The nomination was filed, the scoping review was produced, and the panel has not convened. In a regulated market, that limbo is not safety clearance and it is not approval. It means a decision has not been made yet. The compound that never made it to the panel is not the one that got away. It is the one still waiting on a verdict. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.